Research Assistant Professor of Pharmacology
Bio
Lamiaa El-Shennawy, PhD, studies the role of cancer-derived extracellular vesicles in triple negative breast cancer. Dr. El-Shennawy’s work has been published in high impact journals, such as Cancer Discovery, Nature Communications, and Cancer Research. Her contributions and potentials have been recognized by several outstanding awards, such as Ruth L. Kirschstein National Research Service Award (NRSA), Susan G. Komen Scholar‐In‐Training Award, and the prestigious International Fulbright Science and Technology Award. Dr. El-Shennawy joined Northwestern University in 2019 as a postdoctoral fellow then she was appointed the position of a Research Assistant Professor in 2023.
Triple negative breast cancer (TNBC), accounting for up to 20% of all breast tumors, is highly metastatic and more aggressive than other breast cancer subtypes, leading to lower survival rates than other breast cancer types due to limited treatment options. Like other tumors, TNBC secretes tumor extracellular vesicles (TEVs), which promote tumor progression and metastasis, but can also be used as a diagnostic biomarkers and therapeutic targets. This study seeks to use TEVs to enhance the patient’s immune system against the tumor in a specific and personalized manner to support the treatment of TNBC.
"The Lynn Sage Foundation didn't just fund our research—they believed in us when the work was uncertain. That faith made all the difference in getting this treatment to patients."
Lamiaa El-Shennawy, PhD
Northwestern University Feinberg School of Medicine
Current
Early Investigator
Andrew Hoffmann, PhD
AI-enabled Profiling of Circulating Tumor-Immune Ecosystems Predicts Breast Cancer Outcomes
Current
Early Investigator
Frederick Howard, MD
Predicting Breast Cancer Recurrence in the Chicagoland Area Using Artificial Intelligence
Current
Early Investigator
Jeffrey Schneider, PhD
Breaking Barriers in Breast Cancer Therapy Through Individualized Immune Profiling
Why your gift matters
Your gift helps researchers test bold ideas, generate critical data, and take the first steps toward the next major advancement in breast cancer treatment and care.Together, we can accelerate discoveries that save lives.
